Cetuximab β Combined With PRaG Regimen in the Treatment of EGFR-positive Advanced Refractory Solid Tumors

Phase 2 Not yet recruiting 40 enrolled Second Affiliated Hospital of Soochow University

NaSingle-groupOpen-labelTreatment

Summary

This study is a single-arm, multi-center, prospective clinical study aimed at exploring the efficacy and safety of cetuximab β combined with PRaG regimen in rescuing patients with EGFR-positive advanced refractory solid tumors.

Timeline

Start: 2025-12-27
Primary completion: 2027-02-10
Completion: 2027-11-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cetuximab β	Monoclonal antibody	500 mg/m2	—
Background	Envafolimab	Monoclonal antibody	400 mg	—
Background	sargramostim	Protein / enzyme biologic	200 ug	—

Cetuximab β Combined With PRaG Regimen in the Treatment of EGFR-positive Advanced Refractory Solid Tumors

Summary

Timeline

Drugs

Indications